The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Improving Delivery of Parkinson's Disease Therapeutics to th, 2008Deep brain imaging to determine movement of compounds relevant to Parkinson's disease
Objective/Rationale:
Clinical trials with a number of agents suggest that the ability of compounds to move through the interstitial spaces of the brain is a critical factor for their effectiveness... -
Improving Delivery of Parkinson's Disease Therapeutics to th, 2008Novel Antibodies for the Delivery of Parkinson's Therapeutics
Objective/Rationale:
Hindering drug development for neurological diseases like Parkinson’s disease is a lack of robust drug delivery strategies that can target medicines to the brain noninvasively via... -
Improving Delivery of Parkinson's Disease Therapeutics, 2008Utilizing Novel Tracers to Determine the Distribution of Therapeutic Agents In Vivo
Objective/Rationale:
This project will study the delivery and distribution of promising therapeutics for Parkinson’s disease. The explored compounds will be infused directly into the brain of npre... -
Improving Delivery of Parkinson's Disease Therapeutics to th, 2008Intranasal Delivery of GDNF for Parkinson's Disease: Next Steps
Objective/Rationale:
GDNF, a naturally-occurring growth factor capable of protecting and promoting the survival of dopamine neurons, has great potential as a treatment for Parkinson’s disease. However... -
MJFF Research Grant, 2008DNA Nanoparticle Therapy for Parkinson’s Disease
Promising Outcomes of Original Grant:
Recombinant plasmid DNA encoding for glial cell line-derived neurotrophic factor (GDNF) was compacted into nanoparticles, injected safely into the brain, and... -
Rapid Response Innovation Awards, 2008Development of modulators of alpha-synuclein conformation for PD therapeutics
Promising Outcomes of Original Grant:
Our Rapid Response Innovation Award (RRIA) enabled us to develop a conformational change assay for monomeric alpha-synuclein. We identified positive and negative...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.